Summary of patients and clinical trials in the all-exposed safety population.
MTX, methotrexate; IR, inadequate responder; TCZ, tocilizumab; TNF, tumor necrosis factor; DMARD, disease-modifying antirheumatic drug.
* Includes patients in the control arm of study.
† All-exposed population = all patients who have received at least one dose of TCZ in the controlled phase or extension studies.
Source: van Vollenhoven et al. [2009b]. ACR Oral presentation no. 1955.